Retractable Tech Stock Price, News & Analysis

Retractable Technologies (NYSE: RVP) announced its EasyPoint® Blood Collection Tube Holder with Needle received an Innovative Technology designation from Vizient on November 14, 2025. Vizient's client-led councils designate previously contracted products that may enhance clinical care, patient safety, worker safety, or healthcare operations.

The EasyPoint BCTH uses automated in-vein retraction, a pre-attached needle, an integrated low-profile safety mechanism, and one-handed activation to reduce needlestick exposure, streamline workflow, and render the device non-reusable once activated.

Retractable Technologies (NYSE American: RVP) has declared quarterly dividends for its Series II and Series III Class B Convertible Preferred Stock shareholders. The company will pay $39,050.00 to Series II holders and $18,561.25 to Series III holders, reflecting an accrual rate of $1.00 per share per annum for Q3 2025.

The dividends will be paid on October 20, 2025 to shareholders of record as of October 10, 2025. Retractable Technologies specializes in manufacturing safety medical products including VanishPoint®, Patient Safe®, and EasyPoint® needle products designed to prevent needlestick injuries and reduce infection risks.

Retractable Technologies (NYSE American: RVP) reported Q2 2025 financial results, with total net sales of $10.4 million, up from $6.0 million in Q2 2024, despite an operating loss of $5.1 million. For H1 2025, net sales reached $18.7 million, compared to $13.6 million in H1 2024, with operating losses of $9.8 million.

The company faces significant challenges from Chinese import tariffs of 130% on needles and syringes, spending $2.1 million on tariffs in H1 2025. In response, RVP has increased U.S. production to 38% of total manufacturing, up from 9% in 2024. The company implemented workforce reductions to offset higher domestic manufacturing costs. A notable $1.9 million litigation settlement was received in Q2 2025, while the company recorded an unrealized loss of $5.6 million on investments.

Retractable Technologies (NYSE American: RVP) has announced a 12.4% reduction in its manufacturing workforce. The company expects to save approximately $1.6 million in annual wages and benefits, representing an 8.6% reduction in total workforce costs, offset by one-time separation payments of $56,000.

The workforce reduction primarily affects manufacturing and support positions as RVP balances domestic production against Chinese imports. The decision comes as the company grapples with significant tariff impacts on Chinese imports, leading to increased focus on domestic production at its Little Elm facility while continuing to import only products that cannot be manufactured domestically.

Retractable Technologies (NYSE American: RVP) has declared dividends for its Series II Class B and Series III Class B Convertible Preferred Stock shareholders. The company will pay $39,050.00 to Series II holders and $18,561.25 to Series III holders, with dividends accruing at $1.00 per share annually.

The dividends cover the period from April 1, 2025, through June 30, 2025, and will be paid on July 21, 2025, to shareholders of record as of July 10, 2025. The company specializes in manufacturing safety medical products including VanishPoint®, Patient Safe®, and EasyPoint® needle products designed to prevent needlestick injuries and reduce infection risks.

Retractable Technologies (NYSE American: RVP) reported Q1 2025 financial results with total net sales of $8.3 million, up from $7.6 million in Q1 2024. However, the company faced an increased operating loss of $4.7 million compared to $3.0 million loss in the prior year. The company significantly reduced its Chinese manufacturing dependency to 62.7% from 90.4% by increasing domestic production, though this led to higher costs. Domestic sales represented 89.6% of total revenues, with an 11.9% increase in domestic revenues and 17.2% increase in domestic unit sales. The company incurred $1.5 million in tariff expenses and reported a substantial $7.2 million unrealized loss on debt and equity securities due to decreased market values.

Retractable Technologies (RVP) has announced a 7% reduction in its workforce, which is expected to generate annual savings of $1.6 million in wages and benefits, representing 7.8% of total estimated workforce costs. The restructuring includes one-time separation payments of $300,000 to affected workers.

The workforce reduction primarily impacts general and administrative functions (72%), with the remainder affecting manufacturing positions. This strategic move aligns with RVP's efforts to increase U.S. manufacturing capabilities and reduce dependence on Chinese production, driven by the significant financial impact of tariffs on Chinese imports.

The company plans to focus production at its Little Elm facility while strategically importing only products that cannot be manufactured domestically.

Retractable Technologies (RVP) reported significant financial challenges for 2024, with revenues declining 24.2% to $33.0 million from $43.5 million in the previous year. Domestic revenues fell 15.1% due to lower average selling prices and higher distribution costs, while international revenues dropped 59.1% primarily from reduced vaccination-related sales.

The company posted a substantial operating loss of $21.1 million, compared to $11.5 million loss in 2023. Cash position decreased by $8.4 million, ending 2024 at $4.2 million, with $40.3 million in debt and equity securities. Operating costs remained elevated due to facility expansion and increased domestic production efforts related to 2024-2025 tariffs.

The company faces additional challenges with tariff expenses, spending $1.6 million from September-December 2024 under 100% tariff rates on Chinese imports. Future expenditures include $1 million for equipment and $3.8 million for workforce expansion to boost domestic production.

Retractable Technologies (NYSE American: RVP) has announced dividend declarations for its Series II and Series III Class B Convertible Preferred Stock shareholders. The dividends, accruing at $1.00 per share annually, amount to $39,050.00 and $18,561.25 respectively for Q1 2025.

The dividends cover January 1, 2025 through March 31, 2025, with payment scheduled for April 21, 2025. Shareholders of record as of April 10, 2025 will be eligible. The company specializes in safety medical products including VanishPoint®, Patient Safe®, and EasyPoint® needles, designed to prevent needlestick injuries and reduce infection risks.